A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

Trial Profile

A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Hydroxyprogesterone (Primary) ; Hydroxyprogesterone
  • Indications Preterm labour
  • Focus Pharmacokinetics
  • Sponsors AMAG Pharmaceuticals
  • Most Recent Events

    • 27 Nov 2017 Primary endpoint (Comparison of the maximum plasma concentration (Cmax)) has not been met as per the results published in the Clinical Therapeutics.
    • 27 Nov 2017 Primary endpoint (Comparison of areas under the curve (AUC) to the last time with a concentration LLOQ [AUC0-t] and to infinity [AUCinf])has been met as per the results published in the Clinical Therapeutics.
    • 27 Nov 2017 Results assessing bioavailability of hydroxyprogesterone caproate administered as a subcutaneous injection published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top